Literature DB >> 8682428

[Treatment of persistent diarrhea with S. boulardii in returning travelers. Results of a prospective study].

A Kirchhelle1, N Frühwein, D Tobüren.   

Abstract

AIM: The efficacy and tolerability of Saccharomyces boulardii (S.b.) were investigated in patients with diarrhea contracted while travelling abroad.
METHOD: The efficacy of S.b. was determined on the basis of the frequency and consistency of stools (fewer than 3 unformed stools a day), and symptom changes. A total of 95 patients (49 females, 46 males) aged between 19 and 69 (mean age 32) years were treated with S.b. at a daily dose of between 150 and 450 mg (mean 428 mg) (3 x 1-3 capsules).
RESULTS: Prior to admission to the study, diarrhea had persisted for an average of 11 days; under treatment with S.b. it cleared up after a mean of 5 days. A tendency towards greater efficacy in patients returning from The Middle East and South America was noted. Tolerability was assessed to be very good or good by almost all participants, with side effects occurring in only 2 cases.
CONCLUSION: The study demonstrates that S.b. is both effective and well tolerated when used for the treatment of persistent diarrhea (mean duration 11 days) that had often failed (67% of the cases) to respond to previous antidiarrheal or antibiotic drugs.

Entities:  

Mesh:

Year:  1996        PMID: 8682428

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  4 in total

Review 1.  Microecologic approaches for traveler's diarrhea, antibiotic-associated diarrhea, and acute pediatric diarrhea.

Authors:  L V McFarland
Journal:  Curr Gastroenterol Rep       Date:  1999-08

2.  Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.).

Authors:  M J McCullough; K V Clemons; J H McCusker; D A Stevens
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

3.  Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.

Authors:  Thomas W Hoffmann; Hang-Phuong Pham; Chantal Bridonneau; Camille Aubry; Bruno Lamas; Camille Martin-Gallausiaux; Marco Moroldo; Dominique Rainteau; Nicolas Lapaque; Adrien Six; Mathias L Richard; Emilie Fargier; Marie-Emmanuelle Le Guern; Philippe Langella; Harry Sokol
Journal:  ISME J       Date:  2015-07-28       Impact factor: 10.302

4.  Enterobacteriaceae are essential for the modulation of colitis severity by fungi.

Authors:  Bruno Sovran; Julien Planchais; Sarah Jegou; Marjolene Straube; Bruno Lamas; Jane Mea Natividad; Allison Agus; Louise Dupraz; Jérémy Glodt; Grégory Da Costa; Marie-Laure Michel; Philippe Langella; Mathias L Richard; Harry Sokol
Journal:  Microbiome       Date:  2018-09-01       Impact factor: 14.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.